CDK4 and neoplasm: This approach identified multiple different components of the canonical Wnt pathway that modulate the response to single agent tankyrase inhibitor exposure as well as demonstrating that MSC2504877 can enhance tumour cell responses to inhibitors of the G1 restriction point kinases CDK4 and CDK6, including the licensed cancer drug palbociclib.